Y Intercept Hong Kong Ltd Sells 2,015 Shares of United Therapeutics Corporation (NASDAQ:UTHR)

Y Intercept Hong Kong Ltd trimmed its position in United Therapeutics Corporation (NASDAQ:UTHR - Free Report) by 32.7% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 4,155 shares of the biotechnology company's stock after selling 2,015 shares during the quarter. Y Intercept Hong Kong Ltd's holdings in United Therapeutics were worth $1,281,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Vanguard Group Inc. boosted its holdings in shares of United Therapeutics by 0.7% during the fourth quarter. Vanguard Group Inc. now owns 4,441,823 shares of the biotechnology company's stock worth $1,567,253,000 after purchasing an additional 32,213 shares during the period. FMR LLC boosted its holdings in shares of United Therapeutics by 36.5% during the fourth quarter. FMR LLC now owns 1,471,405 shares of the biotechnology company's stock worth $519,170,000 after purchasing an additional 393,777 shares during the period. Geode Capital Management LLC boosted its holdings in shares of United Therapeutics by 4.0% during the fourth quarter. Geode Capital Management LLC now owns 1,138,292 shares of the biotechnology company's stock worth $401,184,000 after purchasing an additional 44,277 shares during the period. AQR Capital Management LLC boosted its holdings in shares of United Therapeutics by 0.8% during the fourth quarter. AQR Capital Management LLC now owns 975,444 shares of the biotechnology company's stock worth $344,176,000 after purchasing an additional 7,710 shares during the period. Finally, Alliancebernstein L.P. boosted its holdings in shares of United Therapeutics by 28.5% during the fourth quarter. Alliancebernstein L.P. now owns 709,043 shares of the biotechnology company's stock worth $250,179,000 after purchasing an additional 157,363 shares during the period. 94.08% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on the stock. Bank of America cut their price objective on shares of United Therapeutics from $321.00 to $315.00 and set a "neutral" rating on the stock in a research report on Wednesday, June 11th. Wells Fargo & Company reaffirmed an "equal weight" rating and set a $314.00 price objective (down previously from $395.00) on shares of United Therapeutics in a research report on Friday, April 25th. UBS Group cut their price objective on shares of United Therapeutics from $410.00 to $385.00 and set a "buy" rating on the stock in a research report on Monday, June 30th. Morgan Stanley cut their price objective on shares of United Therapeutics from $348.00 to $328.00 and set an "equal weight" rating on the stock in a research report on Thursday, July 10th. Finally, JPMorgan Chase & Co. cut their price objective on shares of United Therapeutics from $350.00 to $330.00 and set an "overweight" rating on the stock in a research report on Tuesday, July 8th. Four equities research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. According to data from MarketBeat.com, United Therapeutics currently has a consensus rating of "Moderate Buy" and an average price target of $383.08.

United Therapeutics Stock Performance

Shares of NASDAQ:UTHR traded down $1.91 on Friday, hitting $304.50. The stock had a trading volume of 310,921 shares, compared to its average volume of 372,488. United Therapeutics Corporation has a twelve month low of $266.98 and a twelve month high of $417.82. The firm's 50 day moving average price is $300.01 and its 200-day moving average price is $316.20. The company has a market capitalization of $13.74 billion, a price-to-earnings ratio of 12.15, a price-to-earnings-growth ratio of 6.68 and a beta of 0.53.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last issued its earnings results on Wednesday, April 30th. The biotechnology company reported $6.63 EPS for the quarter, beating the consensus estimate of $6.29 by $0.34. The company had revenue of $794.40 million for the quarter, compared to the consensus estimate of $726.82 million. United Therapeutics had a net margin of 40.44% and a return on equity of 19.33%. The firm's revenue for the quarter was up 17.2% compared to the same quarter last year. During the same quarter in the previous year, the company earned $6.17 EPS. As a group, sell-side analysts predict that United Therapeutics Corporation will post 24.48 EPS for the current year.

Insider Activity at United Therapeutics

In related news, Director Nilda Mesa sold 645 shares of the company's stock in a transaction dated Tuesday, June 24th. The shares were sold at an average price of $289.99, for a total transaction of $187,043.55. Following the transaction, the director owned 4,883 shares in the company, valued at $1,416,021.17. This represents a 11.67% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Richard Giltner sold 3,036 shares of the company's stock in a transaction dated Tuesday, June 24th. The stock was sold at an average price of $289.60, for a total transaction of $879,225.60. Following the transaction, the director owned 19,384 shares in the company, valued at approximately $5,613,606.40. This trade represents a 13.54% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 81,681 shares of company stock worth $24,628,589 in the last 90 days. Corporate insiders own 10.30% of the company's stock.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.